|
Clinical Data From Phase II Study in Early Breast Cancer Suggests Potential Use of Herceptin With Navelbine as reported at the annual meeting of the American Society of Clinical Oncology (ASCO)
Second study presented at ASCO demonstrates that patients with HER-2 metastatic breast cancer can respond to treatment with Herceptin REGARDLESS of their estrogen receptor (ER) status.
|